Zobrazeno 1 - 10 of 32 357 pro vyhledávání: '"mCRPC"'
1
Akademický článek
Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval.
Autor: Karimzadeh, Amir1,2 (AUTHOR) amir.karimzadeh@uke.de, Hecker, Charlotte-Sophie1 (AUTHOR), Heck, Matthias M.3 (AUTHOR), Tauber, Robert3 (AUTHOR), D'Alessandria, Calogero1 (AUTHOR), Weber, Wolfgang A.1 (AUTHOR), Eiber, Matthias1 (AUTHOR), Rauscher, Isabel1 (AUTHOR)
Publikováno v: EJNMMI Research. 10/14/2024, Vol. 14 Issue 1, p1-10. 10p.
Zobrazit plný text záznamu
2
Akademický článek
Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy.
Autor: Burgard, Caroline1 (AUTHOR) caroline.burgard@uks.eu, Khreish, Fadi1,2 (AUTHOR) s8lsdahl@stud.uni-saarland.de, Dahlmanns, Lukas1 (AUTHOR) arne.blickle@uni-saarland.de, Blickle, Arne1 (AUTHOR) moritz.bastian@uks.eu, Bastian, Moritz B.1 (AUTHOR) tilman.speicher@uks.eu, Speicher, Tilman1 (AUTHOR) stephan.maus@uks.eu, Maus, Stephan1 (AUTHOR) andrea.schaefer@uks.eu, Schaefer-Schuler, Andrea1 (AUTHOR) mark.bartholomae@uks.eu, Bartholomä, Mark1 (AUTHOR) sven.petto@uks.eu, Petto, Sven1 (AUTHOR) samer.ezziddin@uks.eu, Ezziddin, Samer1 (AUTHOR) florian.rosar@uks.eu, Rosar, Florian1 (AUTHOR)
Publikováno v: Cancers. Oct2024, Vol. 16 Issue 20, p3532. 12p.
Zobrazit plný text záznamu
3
Akademický článek
Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis.
Autor: Farinea, Giovanni1 (AUTHOR) giovanni.farinea@unito.it, Calabrese, Mariangela1 (AUTHOR) federicamaria.carfi@unito.it, Carfì, Federica1 (AUTHOR) isabella.saporita@unito.it, Saporita, Isabella1 (AUTHOR) stefano.poletto@unito.it, Poletto, Stefano1 (AUTHOR) donatello.m.delcuratolo@gmail.com, Delcuratolo, Marco Donatello1 (AUTHOR) marco.audisio@unito.it, Turco, Fabio2 (AUTHOR) fabio.turco@eoc.ch, Audisio, Marco1 (AUTHOR) rosario-distefano@virgilio.it, Di Stefano, Francesco Rosario1 (AUTHOR) consuelo.buttigliero@unito.it, Tucci, Marcello3 (AUTHOR) marcello.tucci@gmail.com, Buttigliero, Consuelo1 (AUTHOR)
Publikováno v: Cells (2073-4409). Aug2024, Vol. 13 Issue 16, p1396. 13p.
Zobrazit plný text záznamu
4
Akademický článek
Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study.
Autor: Chen, Sijin1 (AUTHOR), Zhong, Dewen2 (AUTHOR), Yu, Chenbo3,4 (AUTHOR), Cai, Desheng3,4 (AUTHOR), Wei, Qichen5 (AUTHOR), Yang, Minggen6 (AUTHOR), Li, Tao3,4 (AUTHOR), Zhu, Qingguo3,4 (AUTHOR), Ye, Liefu3,4 (AUTHOR), Wei, Yongbao3,4 (AUTHOR) weiyb@fjmu.edu.cn, Wu, Jinfeng3,4 (AUTHOR) 32252641@qq.com
Publikováno v: Scientific Reports. 8/27/2024, Vol. 14 Issue 1, p1-6. 6p.
Zobrazit plný text záznamu
6
Akademický článek
[Therapy sequences and duration in mCRPC: a retrospective review of the Lübeck mCRPC cohort].
Autor: Müller M; Urologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Luebeck, Germany., Sarcan S; Urologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Luebeck, Germany., Offermann A; Pathologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck und Forschungszentrum Borstel, Leibniz Lungenzentrum, Lübeck, Germany., Kang D; Pathologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany., Wießmeyer JR; Urologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Luebeck, Germany., Kramer M; Urologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Luebeck, Germany., Merseburger AS; Urologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Luebeck, Germany., Roesch MC; Urologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Luebeck, Germany.
Publikováno v: Aktuelle Urologie [Aktuelle Urol] 2024 Jun 25. Date of Electronic Publication: 2024 Jun 25.
Zobrazit plný text záznamu
7
Akademický článek
Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval
Autor: Amir Karimzadeh, Charlotte-Sophie Hecker, Matthias M. Heck, Robert Tauber, Calogero D’Alessandria, Wolfgang A. Weber, Matthias Eiber, Isabel Rauscher
Publikováno v: EJNMMI Research, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Background The optimal regimen for 177Lu-labeled prostate-specific membrane antigen-targeted radioligand therapy, including treatment intervals, remains under study, with evidence suggesting shorter intervals could benefit patients with high
Externí odkaz: https://doaj.org/article/31e329c31e0949a1906aa3f3aad0cf6d
Zobrazit plný text záznamu
8
Akademický článek
Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Autor: Rosar, Florian1 (AUTHOR), Burgard, Caroline1 (AUTHOR), David, Scott1 (AUTHOR), Marlowe, Robert J.2 (AUTHOR), Bartholomä, Mark1 (AUTHOR), Maus, Stephan1 (AUTHOR), Petto, Sven1 (AUTHOR), Khreish, Fadi1 (AUTHOR), Schaefer-Schuler, Andrea1 (AUTHOR), Ezziddin, Samer1 (AUTHOR) samer.ezziddin@uks.eu
Publikováno v: Scientific Reports. 5/17/2024, Vol. 14 Issue 1, p1-11. 11p.
Zobrazit plný text záznamu
9
Akademický článek
The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
Autor: Zhu, Qiyu1 (AUTHOR), Chen, Junru1 (AUTHOR), Liu, Haoyang1 (AUTHOR), Zhao, Jinge1 (AUTHOR), Xu, Chenhao1 (AUTHOR), Sun, Guangxi1 (AUTHOR) sungx077@126.com, Zeng, Hao1 (AUTHOR) zengh@scu.edu.cn
Publikováno v: BMC Cancer. 6/8/2024, Vol. 24 Issue 1, p1-10. 10p.
Zobrazit plný text záznamu
10
Akademický článek
Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study
Autor: Sijin Chen, Dewen Zhong, Chenbo Yu, Desheng Cai, Qichen Wei, Minggen Yang, Tao Li, Qingguo Zhu, Liefu Ye, Yongbao Wei, Jinfeng Wu
Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-6 (2024)
Abstract Although overall survival data are still premature, the PROpel study found radiological progression-free survival (PFS) benefits of abiraterone and olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). However, f
Externí odkaz: https://doaj.org/article/5ca27f5ab8044e2fb1dc37c979b5226b
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje